Navigation Links
ACT to Be Issued Broad Patent for Human ES Cell-derived RPE Cells in China
Date:3/23/2011

MARLBOROUGH, Mass., March 23, 2011 /PRNewswire/ -- Advanced Cell Technology, Inc. ("ACT"; OTC Bulletin Board: ACTC), a leader in the field of regenerative medicine, announced today that China's State Intellectual Property Office (SIPO) has allowed the Company's patent application to provide broad intellectual property protection in China for the manufacturing and pharmaceutical preparations of retinal pigment epithelial (RPE) cells from human embryonic stem cells (hESCs).  

This Chinese patent filing provides coverage of the scalable manufacturing of human RPE cells from hESCs.  The claims cover methods for producing purified preparations of RPE cells from hESCs, and the use of those hESC-derived RPE cells in pharmaceutical preparations and compositions.

"The fact that we are being awarded a set of broad claims in China, following the issuance of the three far-reaching RPE patents in the U.S. last year, gives us greater confidence that we are in a position to create a dominant patent position around our stem cell-derived RPE program in leading markets around the world," said Gary Rabin, ACT's interim chairman and CEO. "Our progress in obtaining patent protection in China for our RPE program is a testament to the continued recognition of the inventions and innovations resulting from our scientific team's ongoing research, and further protects the platform technology underlying one of our key therapeutic programs."  

The efficient production of highly pure RPE cell preparations derived from human embryonic stem cells represents the first critical step in the creation of a renewable source of transplantable cells that can be used to target macular degenerative diseases such as Stargardt's Macular Dystrophy (SMD) and Dry Age-related Macular Degeneration (Dry AMD). The Company has already demonstrated that its hESC-derived RPE cells can rescue visual
'/>"/>

SOURCE Advanced Cell Technology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
2. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
3. Arobella Medical CEO is Issued U.S. Patent for Ultrasound Wound Therapy Technology
4. Prometheus Strengthens Intellectual Property Portfolio with Newly Issued Patents for Thiopurine Metabolite Testing
5. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
6. Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate
7. Details Issued Today on $1 Billion in Biotech Tax Credits and Grants
8. Transave Issued Key Composition of Matter Patent for ARIKACE™
9. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
10. Sustainable Technology Company Cerealus and University of Maine Issued Patent for "Barrier Compositions and Articles"
11. Australian Patent Issued to CreAgri® for Ultraviolet Radiation (UVR) Protection by its Hydroxytyrosol-Based Formulations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sep. 02, 2015 ... the addition of Jain PharmaBiotech,s new report "Gene ... offering. The markets for gene therapy are ... gene therapy product and it is marketed in ... are estimated for the years 2014-2024. The estimates are ...
(Date:9/2/2015)... CHARLOTTESVILLE, Virginia , September 2, 2015 ... sponsoring of the winners of the 2015 BeHEARD science ... Institute that offers rare disease researchers, access to the ... will use its drug repositioning and pathway analytics capability ... at Wylder Nation Foundation in the study of Niemann-Pick ...
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, Inc., ... in the multicenter Phase 2 clinical trial of ... treatment of recurrent subfoveal choroidal neovascularization secondary to ... a unique vascular endothelial growth factor (VEGF) receptor ... "This landmark proof-of-concept study will evaluate ...
(Date:9/2/2015)... -- Aytu BioScience, Inc. (OTCQB: AYTU), a specialty healthcare ... conditions, announced today that it has closed the final ... raising a total of $5.175 million, which includes proceeds ... Josh Disbrow , Chief Executive Officer of ... to be used to conduct clinical studies for both ...
Breaking Biology Technology:Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3
... China , May 17 /PRNewswire-Asia-FirstCall/ -- Shengtai,Pharmaceutical, ... and distributor in China of glucose and starch ... that it issued financial results for the third quarter of ... before the opening of the stock,market in USA on ...
... ,, PLEASANTON, Calif. , May 17 TriReme ... for an expanded matrix of sizes for its GliderXtreme™ PTA balloon ... lesions in the peripheral vasculature in balloon diameters from 2.0 – ... , , ...
... ViroPharma Incorporated (Nasdaq: VPHM ) today announced that it ... to prevent attacks of hereditary angioedema (HAE), with West Pharmaceutical Services, ... simple-to-use reconstitution device and accompanying training materials will be widely available ... , , ...
Cached Biology Technology:Shengtai Pharmaceutical Schedules Fiscal Year 2010 Third Quarter Financial Results Conference Call 2Shengtai Pharmaceutical Schedules Fiscal Year 2010 Third Quarter Financial Results Conference Call 3TriReme Medical, Inc. Receives FDA 510(k) Clearance for a Broad Matrix of GliderXtreme(TM) PTA Balloon Catheter Sizes 2ViroPharma Introduces New Reconstitution System for Cinryze™ (C1 Esterase Inhibitor [Human]) 2ViroPharma Introduces New Reconstitution System for Cinryze™ (C1 Esterase Inhibitor [Human]) 3ViroPharma Introduces New Reconstitution System for Cinryze™ (C1 Esterase Inhibitor [Human]) 4ViroPharma Introduces New Reconstitution System for Cinryze™ (C1 Esterase Inhibitor [Human]) 5
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions ... the entire spectrum of clinical research, is proud to ... the company,s comprehensive SaaS-based eClinical technology platform, has led ... the first two quarters of 2015.   Q2 2015 ... largest quarters measured by contract value sold in the ...
(Date:8/10/2015)... Germany , August 10, 2015 /PRNewswire/ ... world leader in Eye Tracking Technology for more than ... Eye Tracking Platform for integration into all consumer display ... designs for seamless integration of eye tracking into consumer ... and augmented reality smart glasses. Omnivision,s leading sensor technology ...
(Date:8/5/2015)... 5, 2015 According to a ... Market by Software, Services, Vertical (BFSI, Airport, IT & Telecom, ... Global Forecast to 2020", published by MarketsandMarkets, defines and ... into various segments. The global PIAM Market is estimated ... Million by 2019, at a CAGR of 14.9 % ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... gone underground to get the most top secret information ... in his experimental orchards, and it is sort of ... is part of a national specialty crop research project ... Texas AgriLife Research horticultural scientist, will focus on pecans ...
... causes temperatures to increase in Hawaii,s mountains, deadly ... the mountains, invading most of the last disease-free ... and remarkable birds. A just-published U.S. ... a forthcoming "disease invasion" by examining the present ...
... around the world will convene at the University of ... from the most ambitious effort ever undertaken to measure ... they contribute in the near term to the dramatic ... two-year international field campaign known as POLARCAT was conducted ...
Cached Biology News:Getting to the root of science in a nutty way 2Jeepers creepers: Climate change threatens endangered honeycreepers 2Jeepers creepers: Climate change threatens endangered honeycreepers 3Spring agricultural fires have large impact on melting Arctic 2Spring agricultural fires have large impact on melting Arctic 3
V beta 5 Purified Anti-Human clone MH3-2, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Monoclonal Anti-Cystatin A tissue culture supernatant Solution containing 15 mM sodium azide human cystatin A ...
...
... Building on the ease of use and flexibility of ... Biosciences introduces the BDTM LSR II. The BD ... before in a benchtop analyzer. Free up your ... a UV laser to the BD LSR II. The ...
Biology Products: